Ludivine Houzé, Marc Dhenain, Suzanne Lam, Fanny Petit, Stéphane Haïk, François Mouton-Liger, Jacques Hugon, Julie Dam, Claire Paquet, Ralf Jockers, Erika Cecon
{"title":"阿尔茨海默病患者脑脊液中的Tau种子活性可预测短期认知能力下降。","authors":"Ludivine Houzé, Marc Dhenain, Suzanne Lam, Fanny Petit, Stéphane Haïk, François Mouton-Liger, Jacques Hugon, Julie Dam, Claire Paquet, Ralf Jockers, Erika Cecon","doi":"10.1186/s13195-025-01792-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alzheimer disease (AD) clinical progression is highly heterogeneous, making its prediction essential for the development of effective therapies. The advancement of cognitive decline in AD is tightly linked to the spread of pathological tau protein aggregates in the brain, through tau seeding properties.</p><p><strong>Methods: </strong>We developed a cellular biosensor to measure tau seeding activity from cerebrospinal fluid (CSF) and human brain lysates. Longitudinal analysis of cognitive function was correlated with biosensor response.</p><p><strong>Results: </strong>Individuals with CSF exhibiting high or intermediate seeding activity experienced more rapid cognitive decline compared to those with low seeding. High tau seeding was associated with total and phosphorylated tau biomarkers in AD. The biosensor also predicts the potential of human AD brain lysates to induce tau aggregation upon experimental transmission in animal models.</p><p><strong>Conclusions: </strong>These results suggest that seeding activity might be a relevant biomarker to forecast AD pathogenicity and clinical progression.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"17 1","pages":"145"},"PeriodicalIF":7.6000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220128/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline.\",\"authors\":\"Ludivine Houzé, Marc Dhenain, Suzanne Lam, Fanny Petit, Stéphane Haïk, François Mouton-Liger, Jacques Hugon, Julie Dam, Claire Paquet, Ralf Jockers, Erika Cecon\",\"doi\":\"10.1186/s13195-025-01792-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Alzheimer disease (AD) clinical progression is highly heterogeneous, making its prediction essential for the development of effective therapies. The advancement of cognitive decline in AD is tightly linked to the spread of pathological tau protein aggregates in the brain, through tau seeding properties.</p><p><strong>Methods: </strong>We developed a cellular biosensor to measure tau seeding activity from cerebrospinal fluid (CSF) and human brain lysates. Longitudinal analysis of cognitive function was correlated with biosensor response.</p><p><strong>Results: </strong>Individuals with CSF exhibiting high or intermediate seeding activity experienced more rapid cognitive decline compared to those with low seeding. High tau seeding was associated with total and phosphorylated tau biomarkers in AD. The biosensor also predicts the potential of human AD brain lysates to induce tau aggregation upon experimental transmission in animal models.</p><p><strong>Conclusions: </strong>These results suggest that seeding activity might be a relevant biomarker to forecast AD pathogenicity and clinical progression.</p>\",\"PeriodicalId\":7516,\"journal\":{\"name\":\"Alzheimer's Research & Therapy\",\"volume\":\"17 1\",\"pages\":\"145\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220128/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's Research & Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13195-025-01792-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-025-01792-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline.
Background: Alzheimer disease (AD) clinical progression is highly heterogeneous, making its prediction essential for the development of effective therapies. The advancement of cognitive decline in AD is tightly linked to the spread of pathological tau protein aggregates in the brain, through tau seeding properties.
Methods: We developed a cellular biosensor to measure tau seeding activity from cerebrospinal fluid (CSF) and human brain lysates. Longitudinal analysis of cognitive function was correlated with biosensor response.
Results: Individuals with CSF exhibiting high or intermediate seeding activity experienced more rapid cognitive decline compared to those with low seeding. High tau seeding was associated with total and phosphorylated tau biomarkers in AD. The biosensor also predicts the potential of human AD brain lysates to induce tau aggregation upon experimental transmission in animal models.
Conclusions: These results suggest that seeding activity might be a relevant biomarker to forecast AD pathogenicity and clinical progression.
期刊介绍：
Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
